TY - JOUR
T1 - Lung stereotactic body radiotherapy with an MR-linac – Quantifying the impact of the magnetic field and real-time tumor trackingThe impact of a magnetic field and real-time MLC tumor tracking on lung SBRT
AU - Menten, Martin J.
AU - Fast, Martin F.
AU - Nill, Simeon
AU - Kamerling, Cornelis P.
AU - McDonald, Fiona
AU - Oelfke, Uwe
N1 - Funding Information:
The Institute of Cancer Research is part of the Elekta Atlantic MR-linac Research Consortium and we acknowledge financial and technical support from Elekta AB under a research agreement. However, the sponsors had no part in the design or execution of the study.
Funding Information:
We would like to thank Helen Burland, Alex Dunlop, Vibeke Hansen, Dualta McQuaid, Gregory Smyth and Philip Wai for their help obtaining the patient CT scans and Jamie A. Dean for improving the clarity of this manuscript. Research at The Institute of Cancer Research is supported by Cancer Research UK under Programme C33589/A19727. Martin F. Fast is supported by Cancer Research UK under Programme C33589/A19908. We acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research.
Publisher Copyright:
© 2016 The Author(s)
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Background and purpose There are concerns that radiotherapy doses delivered in a magnetic field might be distorted due to the Lorentz force deflecting secondary electrons. This study investigates this effect on lung stereotactic body radiotherapy (SBRT) treatments, conducted either with or without multileaf collimator (MLC) tumor tracking. Material and methods Lung SBRT treatments with an MR-linac were simulated for nine patients. Two different treatment techniques were compared: conventional, non-tracked deliveries and deliveries with real-time MLC tumor tracking, each conducted either with or without a 1.5 T magnetic field. Results Slight dose distortions at air-tissue-interfaces were observed in the presence of the magnetic field. Most prominently, the dose to 2% of the skin increased by 1.4 Gy on average. Regardless of the presence of the magnetic field, MLC tracking was able to spare healthy tissue, for example by decreasing the mean lung dose by 0.3 Gy on average, while maintaining the target dose. Conclusions Accounting for the magnetic field during treatment plan optimization allowed for design and delivery of clinically acceptable lung SBRT treatments with an MR-linac. Furthermore, the ability of MLC tumor tracking to decrease dose exposure of healthy tissue, was not inhibited by the magnetic field.
AB - Background and purpose There are concerns that radiotherapy doses delivered in a magnetic field might be distorted due to the Lorentz force deflecting secondary electrons. This study investigates this effect on lung stereotactic body radiotherapy (SBRT) treatments, conducted either with or without multileaf collimator (MLC) tumor tracking. Material and methods Lung SBRT treatments with an MR-linac were simulated for nine patients. Two different treatment techniques were compared: conventional, non-tracked deliveries and deliveries with real-time MLC tumor tracking, each conducted either with or without a 1.5 T magnetic field. Results Slight dose distortions at air-tissue-interfaces were observed in the presence of the magnetic field. Most prominently, the dose to 2% of the skin increased by 1.4 Gy on average. Regardless of the presence of the magnetic field, MLC tracking was able to spare healthy tissue, for example by decreasing the mean lung dose by 0.3 Gy on average, while maintaining the target dose. Conclusions Accounting for the magnetic field during treatment plan optimization allowed for design and delivery of clinically acceptable lung SBRT treatments with an MR-linac. Furthermore, the ability of MLC tumor tracking to decrease dose exposure of healthy tissue, was not inhibited by the magnetic field.
KW - Lung stereotactic body radiotherapy
KW - MR-guided radiotherapy
KW - MR-linac
KW - Real-time adaptive radiotherapy
KW - Tumor tracking
UR - http://www.scopus.com/inward/record.url?scp=84975109753&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2016.04.019
DO - 10.1016/j.radonc.2016.04.019
M3 - Article
C2 - 27165615
AN - SCOPUS:84975109753
SN - 0167-8140
VL - 119
SP - 461
EP - 466
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -